{"groups":[{"description":"Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","id":"FG000","title":"Treosulfan and Fludarabine Conditioning"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"60"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"60"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients recruited at OHSU Knight Cancer Institute clinics in Portland, Oregon and Fred Hutchinson Cancer Research Center or University of Washington Medical Center clinics, Seattle, Washington."}